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Enhancing chemosensitivity to gemcitabine via
RNA interference targeting the catalytic subunits
of protein kinase CK2 in human pancreatic cancer
cells
Jan N Kreutzer1, Maria Ruzzene2, Barbara Guerra1*
Abstract
Background: Pancreatic cancer is a complex genetic disorder that is characterized by rapid progression,
invasiveness, resistance to treatment and high molecular heterogeneity. Various agents have been used in clinical
trials showing only modest improvements with respect to gemcitabine-based chemotherapy, which continues to
be the standard first-line treatment for this disease. However, owing to the overwhelming molecular alterations
that have been reported in pancreatic cancer, there is increasing focus on targeting molecular pathways and
networks, rather than individual genes or gene-products with a combination of novel chemotherapeutic agents.
Methods: Cells were transfected with small interfering RNAs (siRNAs) targeting the individual CK2 subunits. The
CK2 protein expression levels were determined and the effect of its down-regulation on chemosensitization of
pancreatic cancer cells was investigated.
Results: The present study examined the impact on cell death following depletion of the individual protein kinase
CK2 catalytic subunits alone or in combination with gemcitabine and the molecular mechanisms by which this
effect is achieved. Depletion of the CK2a or -a′ subunits in combination with gemcitabine resulted in marked
apoptotic and necrotic cell death in PANC-1 cells. We show that the mechanism of cell death is associated with
deregulation of distinct survival signaling pathways. Cellular depletion of CK2a leads to phosphorylation and
activation of MKK4/JNK while down-regulation of CK2a′ exerts major effects on the PI3K/AKT pathway.
Conclusions: Results reported here show that the two catalytic subunits of CK2 contribute differently to enhance
gemcitabine-induced cell death, the reduced level of CK2a′ being the most effective and that simultaneous
reduction in the expression of CK2 and other survival factors might be an effective therapeutic strategy for
enhancing the sensitivity of human pancreatic cancer towards chemotherapeutic agents.
Background
Pancreatic cancer is one of the most aggressive human
solid tumors which rapidly grows and metastasizes,
representing one of the leading causes of cancer-related
death in developed countries [1,2]. Current treatment
regimens for patients with pancreatic cancer that are
not suitable for surgical resection are still not effective,
due to low response rates and a 5-6 months median
survival [1,2]. Over the past decades, multiple rando-
mized trials have sought to improve the outcome of
patients with advanced pancreatic cancer including
treatment with platinum agents, taxanes and topoisome-
rase inhibitors [3]. Moreover, there has been consider-
able interest in combining gemcitabine (2′,2′-difluoro 2′-
deoxycytidine), the first-line treatment option, with
ionizing radiation and a variety of other agents that
exert various mechanisms of action. Based on the
acquired knowledge on the molecular biology of this
disease [4], new approaches (i.e. combination therapy
where chemotherapeutic agents are administered with
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compounds, such as inhibitors, targeting pro-survival
proteins and protein kinases) in pancreatic cancer treat-
ment have recently emerged [5].
Protein kinase CK2 is a serine/threonine kinase, highly
conserved and ubiquitously expressed in eukaryotic
cells. Traditionally, CK2 has been described as a consti-
tutively active enzyme composed of two catalytic a and/
or a′ and two regulatory b subunits [6-8] but mounting
evidence has recently modified the classical view of CK2
as a stable tetrameric complex, revealing that the indivi-
dual CK2 subunits may be asymmetrically distributed
and exert independent functions in cells [9]. The high
degree of conservation of CK2 suggests that this enzyme
might be essential for cell viability. Indeed, complete
suppression of the CK2 a- or b-subunits leads to
embryonic lethality in mice while knockout of CK2a′
results in viable offspring but leads to sterility in male
mice due to defective spermatogenesis [10-12]. Consid-
erable information on the role of CK2 in various dis-
eases has been gained in recent years [8] making it a
promising therapeutic target particularly for the treat-
ment of cancer [13]. CK2 has been involved in neurode-
generative disorders where a number of structural
proteins and enzymes involved in various functions of
the nervous system have been identified as CK2 sub-
strates, in inflammatory processes, in diseases of the vas-
cular system, in various parasites- and viral-related
diseases [8]. Overexpression of CK2 has been documen-
ted in a number of cancers where deregulation of intra-
cellular signaling pathways and association with the
aggressiveness of the tumor have been observed [13].
Cooperative increase in tumorigenesis in cells co-expres-
sing oncogenes and CK2 has also been reported demon-
strating a critical role of CK2 in the progression of
malignancies [6,13].
Recently, the development of a systematic approach by
which over 600 kinases were individually silenced by
small interfering RNAs (siRNAs) revealed that down-
regulation of the CK2 a-subunit increases the sensitivity
of pancreatic cancer cells to gemcitabine [14]. Similarly,
the pharmacological inhibition of CK2 has been shown
to counteract the apoptosis resistance of a T lympho-
blastoid cell line [15].
In this study, we aimed to closely investigate the role
of protein kinase CK2 in human pancreatic cancer cells
highly resistant to chemotherapeutic treatment. We
report evidence that the cellular depletion of CK2a and
-a′ by siRNAs markedly enhances the sensitivity of can-
cer cells to gemcitabine treatment. Moreover, we show
that the individual CK2 catalytic subunits contribute dif-
ferently to the modulation of intracellular survival path-
ways resulting in distinct cellular responses towards
drug treatment.
Methods
Cell culture and treatments
The pancreatic ductal adenocarcinoma cell lines Mia PaCa-
2, PANC-1, BxPC-3 and Capan-1 were purchased from the
American Type Culture Collection and maintained under
the conditions recommended by the supplier. Photographs
of the cells were taken under a phase contrast microscope
(Leica, DM IRB, Germany). Silencing of CK2 expression
was achieved by transfection of cells with siRNA duplexes
directed against the individual catalytic subunits (ON-
TARGET plus SMARTpools, Dharmacon, CO, USA). Cells
were transfected with Lipofectamine 2000 (Invitrogen, CA,
USA) for up to 96 h following the manufacturer’s recom-
mendations. Gemcitabine (Eli Lilly, Germany) treatment
was performed 24 h after transfection for 72 h. Where indi-
cated, cells were incubated for 72 h with the broad range
caspase inhibitor, z-Val-Ala-Asp-fluoromethyl-ketone
[zVAD(OMe)-fmk, Calbiochem, CA, USA] at a concentra-
tion of 5 μM and the cathepsin B inhibitor, z-Phe-Ala-fmk
(zFA-fmk, Calbiochem) at a concentration of 85 μM.
Determination of cell viability and proliferation
The WST-1 viability assay (Roche, Germany) was per-
formed in 96-well plates. Twenty-four hours after seeding,
cells were treated with various concentrations of gemcita-
bine for 72 h. WST-1 reagent was added to the cells
according to the manufacturer’s instructions. Conversion
of the WST-1 reagent into formazan salts by metabolically
active cells was measured 2 h after addition of the reagent
in a microtiter plate reader (Perkin-Elmer, MA, USA). The
Cell Proliferation Assay (Calbiochem) was performed in
96-well tissue culture plates. After 72 h treatment, cells
were labeled with 5-bromo-2′-deoxyuridine (BrdU) for 3 h.
Cells were then fixed, DNA was denatured and cells were
subsequently incubated with a peroxidase-conjugated anti-
BrdU antibody. The immune complexes were revealed in a
microtiter plate reader by the subsequent substrate reac-
tion according to the manufacturer’s instructions.
Flow cytometry
Cells were collected after various treatments by trypsini-
zation, washed with PBS and fixed overnight in 70%
ethanol at -20°C. For cell cycle analysis and determina-
tion of cell death (i.e. sub-G1 region), cells were incu-
bated for 30 min in the dark with 20 μg/ml propidium
iodide (Sigma, MO, USA) and 40 μg/ml RNase A
(Roche) in PBS. Cells were analyzed on a FACS-Calibur
flow cytometer (Becton Dickinson, CA, USA). The
acquired data were analyzed by Cell Quest Pro Analysis
software (Becton Dickinson). For each measurement,
10,000 cells were analyzed. The method allows the
quantification of cells with reduced DNA (i.e. in late
apoptosis or necrosis).
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Western blot analysis and protein kinase assays
Cell lysates were prepared as described in [16]. Proteins
were detected by probing Western blot membranes with
the following antibodies: mouse monoclonal anti-CK2a/
a′, mouse monoclonal anti-CK2b (both from Calbio-
chem); mouse monoclonal anti-b-actin (Sigma); rabbit
polyclonal anti-CK2a′ obtained by immunizing rabbits
with a specific peptide sequence of human CK2a′:
334SQPCADNAVLSSGTAAR350; mouse monoclonal
anti-poly(ADPribose)polymerase (PARP), mouse mono-
clonal anti-mTOR, mouse monoclonal anti-PDK1,
mouse monoclonal anti-AKT, mouse monoclonal anti-
GSK3b (all from BD Biosciences, CA, USA); rabbit poly-
clonal anti-p44/42MAPK, rabbit monoclonal anti-phos-
pho-p44/42MAPK (T202/Y204), mouse monoclonal
anti-phospho-p38MAPK (T180/Y182), rabbit polyclonal
anti-MKK4, rabbit monoclonal anti-c-Jun, rabbit poly-
clonal anti-phospho-c-Jun (S63), mouse monoclonal
anti-phospho-p70 S6 kinase (T389), rabbit polyclonal
anti-phospho-AKT (T308), mouse monoclonal anti-
phospho-AKT (S473), rabbit polyclonal anti-phospho-
GSK3b (S9) (all from Cell Signaling Technology, MA,
USA); rabbit polyclonal anti-p38MAPK, rabbit monoclo-
nal anti-JNK, rabbit polyclonal anti-p70 S6 kinase, (all
from Santa Cruz Biotechnology, CA, USA); rabbit poly-
clonal anti-phospho-JNK (T183, Y185, BioSource, CA,
USA). Expression of major proteins of the autophagy
machinery was analyzed by employing the autophagy
antibody sample kit (Cell Signaling Technology). Rabbit
polyclonal anti-phospho-AKT (S219) antibody was
obtained as described in [17]. Protein-antibody com-
plexes were visualized by a chemiluminescence Western
blot detection system according to the manufacturer’s
instructions (CDP-Star, Applied Biosytems, CA, USA).
Immunoprecipitation experiments were performed
essentially as described in [18]. The activity of protein
kinase CK2 was determined as reported in [16]. The
activity of JNK was tested in a non-radioactive assay
(SAPK/JNK assay kit, Cell Signaling Technology) follow-
ing the manufacturer’s recommendations in the absence
or presence of 20 μM SP600125 inhibitor (Calbiochem).
Statistical analysis
The two-tailed t-test (Student’s t-test) was performed to
evaluate the statistical significance of differences
between the mean of two sets of data.
Results
Cellular response to gemcitabine of various pancreatic
cancer cell lines
Dose-response experiments were performed measuring
metabolically active cells in the absence and presence of
gemcitabine at different concentrations for 72 h, respec-
tively, (Figure 1A). 50 nM gemcitabine induced
cytotoxicity in Mia PaCa-2, BxPC-3 and Capan-1 cells
by reducing the viability to more than 50% while
PANC-1 cells remained unaffected. The anti-prolifera-
tive effect of gemcitabine was also investigated by mea-
suring BrdU incorporation into the newly synthesized
DNA of replicating cells (Figure 1B). 50 nM gemcitabine
exerted a major effect on Mia PaCa-2, BxPC-3 and
Capan-1 cell lines as their proliferation decreased more
than 50%, with respect to control experiments while the
proliferation of PANC-1 cells decreased about 50%. This
is also documented by the analysis of cells by phase
contrast microscopy (Figure 1C). The response to gem-
citabine treatment was also analyzed by flow cytometry
(Figure 2). Cells were treated with various dosages of
gemcitabine for 72 h prior harvesting. Incubation with
50 nM gemcitabine was sufficient to induce either G1/
S- (Capan-1) or S phase cell cycle arrest (Mia PaCa-2,
PANC-1 and BxPC-3) with respect to control cells (CT).
Gemcitabine up to a concentration of 1 μM did not
result in a significant percentage of cells with reduced
DNA levels in any of the analyzed cell lines supporting
the notion that pancreatic cancer cells are highly resis-
tant to chemotherapeutic treatments as previously
reported [19,20].
Down-regulation of protein kinase CK2 enhances
gemcitabine-induced cell death
To investigate the role of CK2 on the gemcitabine-
mediated cellular response, we attempted to down-regu-
late its expression by employing siRNAs targeting the
two individual a and a′ subunits. The most gemcita-
bine-resistant cell line, PANC-1, was chosen in order to
investigate whether CK2 suppression would significantly
enhance the cytotoxic effect of gemcitabine. Protein
expression analysis indicated that down-regulation of
the individual CK2 subunits was visible after 4 days
from the initial siRNA transfection (Figure 3A). Addi-
tionally, down-regulation of CK2a also caused decreased
expression of CK2b, an effect that has been previously
attributed to the tendency of CK2b to undergo rapid
degradation in case of missing assembly with CK2a
[21,22]. Cellular depletion of the individual CK2 cataly-
tic subunits led to a 40% reduction of the CK2 kinase
activity, whereas gemcitabine treatment did not affect
the CK2 activity measured in the control experiment
(Figure 3B). Next, flow cytometry analysis was con-
ducted to measure cell death in response to gemcitabine
treatment in CK2a or -a′ subunit knockdown cells (Fig-
ure 3C). Treatment with 50 nM gemcitabine for 72 h
led to 7% cell death similar to results shown in Figure 2.
Gemcitabine treatment in CK2a or a′- reduced cells
resulted in 14% and 20% cell death, respectively. Addi-
tionally, the sole depletion of CK2a′ but not -a induced
17.5% cell death. Preliminary experiments conducted
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Figure 1 Effect of gemcitabine on viability and proliferation of four human pancreatic cancer cell lines. A. Cells were treated with the
indicated concentrations of gemcitabine for 72 h. Proportions of viable cells measured by the WST-1 assay are shown in arbitrary units as a
difference in absorbance measured at 450 nm and 690 nm (reference) wavelengths, respectively. B. Cell proliferation was determined by BrdU
incorporation into genomic DNA. The results are expressed in percentage relative to the corresponding untreated controls. In both assays, three
separate experiments were performed and data from one representative experiment [mean +/- standard deviation (STD) of four replicates] are
shown. C. Phase contrast microscopy photographs of cells left untreated or incubated with 50 nM gemcitabine for 72 h. Pictures were originally
captured at 400× magnification.
Kreutzer et al. BMC Cancer 2010, 10:440
http://www.biomedcentral.com/1471-2407/10/440
Page 4 of 12
with scramble siRNA neither modified the percentage of
control cells in sub-G1 nor the expression of the indivi-
dual CK2 subunits (data not shown). Overall, these
results show that the individual CK2 subunits do not
affect cell death to the same extent and that the down-
regulation of CK2a′ and not -a is sufficient to kill cells.
Moreover, they indicate that PANC-1 cells are sensitized
to gemcitabine treatment following cellular depletion of
the CK2a subunit by RNA interference. Next, it was
investigated whether knockdown of CK2 in cells treated
with gemcitabine would lead to an apoptotic type of cell
death by looking at the cleavage of the caspase-3/cas-
pase-7 substrate PARP. As shown in Figure 4A, the sole
gemcitabine treatment resulted in a slight PARP clea-
vage which was comparable to the one corresponding to
cells treated with the transfection reagent. Cellular
depletion of the individual CK2 a- and a′ subunits
alone or in combination with gemcitabine resulted in a
slightly higher induction of PARP cleavage. To further
clarify the type of cell death induced by the treatments
described above, flow cytometry analysis of propidium
iodide-stained cells was performed in the presence or
absence of a broad-range caspase inhibitor zVAD-fmk
or cystein cathepsin inhibitor zFA-fmk as indicated in
Figure 4B. The toxicity of gemcitabine in cells depleted
of CK2a and -a′, respectively, was reduced when cells
were treated with zVAD-fmk or zFA-fmk indicating that
the inhibitors partially prevented the toxic effects
induced by the indicated treatments (Figure 4B). Wes-
tern blot analysis of cell lysates performed by employing
a panel of antibodies directed against proteins involved
in autophagy excluded the involvement of this catabolic
process in the observed cell death (Figure 4C). Overall,
these results suggest that both the mitochondrial and
lysosomal death pathways are activated and that the
combination of gemcitabine and siRNAs against the
individual CK2 subunits induces both apoptotic and
necrotic types of cell death.
Down-regulation of the CK2 catalytic subunits negatively
affects survival pathways in gemcitabine-treated cells
To determine the potential involvement of survival pro-
teins in the mechanism of cell death, the expression
and/or phosphorylation levels of the major protein
kinases belonging to the family of mitogen-activated
protein kinases namely p44/42MAPK, p38MAPK and
Figure 2 Effect of gemcitabine on the cell cycle profile of human pancreatic cancer cell lines. Cells were left untreated (CT) or incubated
with increasing concentrations of gemcitabine (Gem) for 72 h. Fixed cells were analyzed by flow cytometry after propidium iodide staining. The
amount of cells in the various phases of the cell cycle is indicated in percentage. Four separate experiments were performed obtaining similar
results and data from one representative experiment are shown.
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Figure 3 Cellular depletion of the individual CK2 catalytic subunits enhances gemcitabine-mediated cell death. A. PANC-1 cells were left
untreated (CT), treated with transfection reagent (TR) or siRNAs against the catalytic a- and a’-subunits of CK2 for 96 h. One day after
transfection, cells were cultured for 72 h in the presence of 50 nM gemcitabine. Total cell lysates (50 μg) were analyzed by Western blot using
the indicated mouse monoclonal antibodies. b-actin was used as control for equal loading. Insert shows Western blot analysis (long
autoradiographic exposure) of whole extracts from cells treated with transfection reagent, CK2a-siRNA or CK2a’-siRNA, using anti-CK2a/a’
antibody. Data shown are representative of three independent experiments. B. Cells were treated as described in A. Total lysates (15 μg) were
subjected to a radioactive CK2 kinase assay with a specific CK2 peptide substrate as described in [14]. The average +/- STD of three independent
experiments are shown. C. Cells treated as described above were fixed, stained with propidium iodide and analyzed by flow cytometry. The
fraction of dead cells expressed in percentage (average from four independent experiments +/- STD) is reported on the ordinate axis after
subtraction of the average sub-G1 value (i.e. 17.5%) of cells treated with transfection reagent. Stars denote statistically significant differences in
the percentage of cell death after treatment with CK2a-siRNA and gemcitabine or CK2a’-siRNA alone or in combination with gemcitabine as
compared to the treatment with the sole gemcitabine (Student’s t-test, P < 0.05). CK2a’-siRNA treatment was tested against CK2a’-siRNA in
combination with gemcitabine (no statistically significant difference). Statistically significant difference was found when comparing gemcitabine
treatment versus control (results not shown).
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Figure 4 Reduced CK2 levels in cells treated with gemcitabine result in apoptotic and necrotic cell death. A. Whole lysates from cells
treated as indicated in the figure were subjected to Western blot analysis of PARP cleavage. Full length PARP (116 kDa) and the corresponding
cleavage product (85 kDa) are indicated. b-actin was used as control for equal loading. B. Cells treated as indicated below the bar graph were
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Jun-amino-terminal kinase (JNK) were analyzed (Figure
5A). Cellular depletion of the individual CK2 catalytic
subunits either alone or in combination with gemcita-
bine did not affect the expression levels and/or the
phosphorylation status of p44/42MAPK and p38MAPK.
Interestingly, down-regulation of CK2a but not -a′ in
combination with gemcitabine, caused a marked
increase in JNK phosphorylation when compared to
cells left untreated, treated with transfection reagent or
with CK2a-siRNA. Gemcitabine treatment caused a
slight increase in the phosphorylation of JNK which was
comparable to the one relative to cells transfected with
CK2a-siRNA, CK2a′-siRNA or CK2a′-siRNA and gem-
citabine. To further demonstrate that in cells depleted
of CK2a, gemcitabine-induced cell death was mediated
by the JNK signaling pathway, a non-radioactive kinase
assay was performed where the activity of endogenous
JNK was tested against a c-Jun (a downstream target of
JNK [23,24]) fusion protein linked to agarose beads. By
employing a phospho-specific antibody directed against
c-Jun, the activation of JNK following the above indi-
cated treatment was verified (Figure 5B). Phosphoryla-
tion of c-Jun was blocked by the addition of the JNK
inhibitor SP600125 (control assay, [25]). Except in cells
depleted of CK2a and treated with gemcitabine, a simi-
lar activation of JNK was not observed with any other
indicated treatment. Overall, these results support the
notion that gemcitabine-induced cell death in cells
depleted of CK2a is specifically mediated through the
JNK signaling pathway in the PANC-1 cell line.
Next, a possible involvement of the mammalian target
of rapamycin (mTOR) signaling pathway, which has
been shown to play a positive role in cell proliferation
and survival [26], was investigated (Figure 6A). Down-
regulation of the individual a- and a′ subunits of CK2,
respectively, resulted in decreased phosphorylation of
p70 S6 kinase (p70S6K), a known downstream target of
Raptor-mTOR [26], with respect to control experiment
and cells treated with gemcitabine. The phosphorylation
level of p70S6K did not further decrease when cells
were additionally treated with gemcitabine. As mTOR is
one of the effectors regulated via the phosphatidylinosi-
tol 3′-kinase (PI3K)/AKT signaling pathway, the expres-
sion and/or phosphorylation status of other PI3K/AKT
pathway-related proteins were also investigated (Figure
6B). The expression of phosphoinositide-dependent pro-
tein kinase-1 (PDK1) and AKT protein kinases, both
downstream effectors of PI3K, remained unchanged. In
line with results shown in Figure 6A, the phosphoryla-
tion of AKT at S473, which is triggered by Rictor-
mTOR complex [26], was also found decreased in cells
depleted of CK2 subunits and in the absence and pre-
sence of gemcitabine, respectively (Figure 6B). Interest-
ingly, while the down-regulation of CK2a resulted in a
slight decrease of AKT phosphorylation at T308, lack of
CK2a′ expression led to a significant suppression of
AKT phosphorylation at this residue which was accom-
panied by decreased phosphorylation of GSK3b. The
addition of gemcitabine did not significantly modify the
phosphorylation status of AKT observed in cells
depleted of the sole CK2 catalytic subunits. The kinase
activity of endogenous PDK1 was examined as T308 is
one of the AKT-primary regulatory phosphorylation
sites targeted by this kinase. Results indicated that the
observed lack of phosphorylation of AKT at T308 in
cells depleted of CK2a′ was not a direct consequence of
decreased activity of endogenous PDK1 (data not
shown). Recently, it has been found that the CK2-
mediated phosphorylation of AKT at S129, by increasing
the association of heat shock protein 90 (Hsp90) to
AKT, contributes to maintain a high T308 phosphoryla-
tion level [17,27]. Western blot analysis was performed
in order to determine whether lack of phosphorylation
of AKT at T308 in CK2a′-knockdown cells was caused
by a reduced phosphorylation of AKT at S129. Results
reported in Figure 6C, indicated that this was indeed the
case. Overall, these results clearly show that not only the
two catalytic subunits of CK2 contribute differently to
enhance gemcitabine-induced cell death, with the
reduced level of CK2a′ being the most effective, but
also that they exert a different effect on pro-survival sig-
naling pathways in gemcitabine-resistant pancreatic can-
cer cells.
Discussion
Gemcitabine-based therapy remains the first-line treat-
ment for both locally advanced and metastatic pancrea-
tic cancer and serves as the standard to which new
treatment regimens are compared. In this study, the
initial investigation of four pancreatic adenocarcinoma
cell lines on the cellular response to increasing concen-
trations of gemcitabine revealed a variable degree of
sensitivity towards drug treatment. Overall, while
Capan-1 and BxPC-3 cell lines were the most affected
by the treatment, PANC-1 cells showed high resistance
towards gemcitabine with respect to viability and prolif-
eration. Cellular depletion of the individual CK2 cataly-
tic subunits in combination with gemcitabine resulted in
enhanced cell death with respect to the sole gemcitabine
treatment. Interestingly, down-regulation of CK2a′ but
not -a, was sufficient to kill the cells and the percentage
of cell death slightly increased when gemcitabine was
added suggesting that CK2a′ may exert a unique func-
tion associated with the control of cell survival. Several
studies reported the tendency of CK2a2b2 but not
CK2a′2b2 to form aggregates suggesting that aggregation
could be a mean to regulate CK2 activity, whereby the
protomer would be the active form and the oligomer
Kreutzer et al. BMC Cancer 2010, 10:440
http://www.biomedcentral.com/1471-2407/10/440
Page 8 of 12
APhospho-p44/42MAPK
(T202/Y204)
anti-p-
p44/42MAPK
p44/42MAPK
Phospho-p38MAPK
(T180/Y182)
p38MAPK
Phospho-JNK
(T183/Y185)
anti-p-JNK
anti-p-p38MAPK
anti-p38MAPK
anti-
p44/42MAPK
JNK
cJun
MKK4
Actin
anti-JNK
anti-cJun
anti-β actin
anti-MKK4
TR G
em
si
R
N
A
+  
G
em
si
R
N
A
+  
G
emC
T
B
C
K
2α
 s
C
K
2α
 si
R
N
A
+
C
K
2α
’s
C
K
2α
’s
iR
N
A
+
Phospho-c-Jun(S63)
c-Junanti-c-Jun
anti-p-c-Jun
TR G
em
A
+ 
G
em
P6
00
12
5
’ s
iR
N
A
A
+ 
G
emC
T
α
 si
R
N
A
C
K
2α
 si
R
N
A
K
2α
 si
R
N
A
+ 
G
em
 +
 S
P
C
K
2α
C
K
2α
’s
iR
N
A
C
K
2α
C
K
Figure 5 Effect of gemcitabine on the MAPK pathway in CK2 subunits-depleted human PANC-1 cells. A. Total cellular proteins (80 μg)
from exponentially growing cells treated as indicated in the figure were subjected to Western blot analysis with antibodies directed against the
proteins or their phosphorylated form as indicated. b-actin was applied as control for equal loading. p44/42MAPK: the upper band is p44MAPK,
the lower one is p42MAPK. B. Whole lysates (1 mg) from cells treated as indicated in the figure were subjected to a non-radioactive kinase
activity assay in the presence of a GST-c-Jun fusion protein linked to glutathione agarose beads. The precipitated complex was subjected to a
phosphorylation assay as described in the materials and methods section. Where indicated, the JNK inhibitor SP600125 was used at a
concentration of 20 μM. The protein and phosphorylation levels of c-Jun were detected by Western blot with the indicated antibodies.
Representative results from three independent experiments are shown.
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Figure 6 Reduced levels of CK2 affect the pro-survival PI3K/AKT and mTOR signaling pathways in PANC-1 cells. A. Western blot analysis
of mTOR signaling pathway-related proteins in PANC-1 cells treated as indicated in the figure. B. Total lysates (80 μg) from cells treated as
shown in the figure, were subjected to Western blot analysis with the indicated antibodies against PI3K/AKT signaling pathway-related proteins.
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would be inactive [28,29]. As shown in Figure 3A
(insert), the expression of CK2a′ is significantly lower
than the one of CK2a. Interestingly, following siRNA
treatment against the individual subunits, a similar
decrease in the kinase activity was observed. Hence, it is
assumed that in PANC-1 cells CK2a′2b2 would be the
prevalent soluble and active tetrameric form. This
would explain the large effect on cell death seen in cells
depleted of CK2a′. Nevertheless, it cannot be excluded
that CK2a′ might be present predominantly as a mono-
mer. In this respect, evidence indicates that the mono-
meric form of CK2 seems to be more effective in
phosphorylating AKT [17] and more implicated in cell
survival and resistance to chemotherapeutic drug treat-
ment [15]. The potential involvement of various protein
kinases was determined and data indicate that gemcita-
bine treatment in cells lacking CK2a specifically leads
to JNK phosphorylation suggesting that the JNK path-
way, whose role in cell death is well established [30,31],
might contribute to cell killing in pancreatic cancer cells
through a cross-talk with CK2a.
Numerous studies have reported that the PI3K/AKT/
mTOR signaling pathway is constitutively active in pan-
creatic cell lines [32-37]. Moreover, previous data
showed that the gemcitabine-resistance mechanism in
PANC-1 cells is associated with amplification of the
gene coding for AKT [30,35]. Lack of expression of the
CK2 catalytic subunits led to suppression of p70S6K
and AKT phosphorylation at the regulatory T389 and
S473 amino acid residues, respectively, suggesting that
mTOR activity is impaired when CK2 expression is sup-
pressed. While these results demonstrated a cross-talk
between CK2 and mTOR, nevertheless they could not
explain the different percentages of cell death achieved
with down-regulation of CK2a and -a′, respectively.
Interestingly, down-regulation of CK2a′ resulted in a
significant decrease in the phosphorylation and activity
of AKT at T308 which was confirmed by the lowered
phosphorylation of GSK3b. The reported difference in
the phosphorylation levels of AKT suggests that the
modulation of AKT activity contributes to the different
amounts of cell death observed following the aforemen-
tioned treatments. Given the fact that the activity of
PDK1 did not vary, the mechanism by which lack of
CK2a′ resulted in suppression of AKT phosphorylation
at T308 remained to be determined. Results reported
here are consistent with previously published data on a
direct involvement of CK2 in the phosphorylation of
AKT at S129 which facilitates AKT binding to Hsp90
chaperone, thus preventing T308 dephosphorylation
[27]. Indeed upon down-regulation of CK2a′, we found
that, the phosphorylation of AKT at S129 was signifi-
cantly reduced.
Conclusions
The findings presented here indicate a general coopera-
tion between CK2 and the PI3K/AKT and MKK4/JNK
pathways in promoting survival of pancreatic cancer
cells. Modulation of expression of the individual CK2
catalytic subunits has various effects on the aforemen-
tioned signaling pathways. Moreover, the data suggest
that inhibition [38] or suppression of CK2 ([14], present
paper) are promising objectives of novel molecular tar-
geting therapies for pancreatic cancer but given the
complex biology of this type of malignancy, the simulta-
neous targeting of several survival pathways would cer-
tainly improve the chances of efficient tumor treatment
and outcomes of patients with pancreatic cancer.
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